{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_8685400_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"008-957-849-945-532"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11724,"type":"PATENT","title":"University of Miami - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":2822,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8376,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: uni* Miami
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 2802
Search Applicants and Owners separately: uni* Miami
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 2802
administering to the neurons in the CNS of said patient an antibody that specifically binds to at least one intracellular component of a mammalian inflammasome,\n
wherein the antibody is administered intravenously, intraperitoneally or intracerebroventricularly,\n
and wherein said inflammation in said patient is treated."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said CNS injury is selected from the group consisting of traumatic brain injury (TBI), stroke and spinal cord injury (SCI)."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein the CNS injury is SCI and administering the antibody results in a decreased spinal cord lesion volume in the patient."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein the CNS injury is stroke and administering the antibody results in a reduced infarct size in the patient."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein administering the antibody results in improvement in motor skills and locomotor function or cognition in the patient."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said intracellular inflammasome component is Apoptosis-associated Spec-like protein containing a Caspase Activating Recruitment Domain (ASC) or Nacht Leucine-Rich-Repeat Protein 1 (NALP1)."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein the antibody binds to an amino acid sequence having at least 85% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, and SEQ ID NO: 4."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said antibody is taken up by said neurons in the CNS."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 8, wherein said antibody is taken up by a carbenoxolone-sensitive mechanism."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the administration of the antibody results in inhibition of inflammasome activation in the patient."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the administration of the antibody results in a reduction of caspase-1 activation and X-Linked Inhibitor of Apoptosis (XIAP) cleavage in the CNS of said patient."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said antibody is formulated with a pharmaceutically acceptable carrier or diluent."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, further comprising measuring at least one functional outcome selected from the group consisting of reduced histopathological damage, reduced cytokine activation, and reduced infarct size."],"number":13,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}